A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patientsMatthew S. Davids, Jennifer R. Brown, David C. Fisher et al.|Leukemia|2020Cited by 36
Activity of mRNA COVID-19 vaccines in patients with lymphoid malignanciesJennifer L. Crombie, Nicolas C. Issa, Matthew S. Davids et al.|Blood Advances|2021Cited by 24
Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid MalignanciesAmy C Sherman, Nicolas C. Issa, Jennifer L. Crombie et al.|Open Forum Infectious Diseases|2022Cited by 10
Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)Christine E. Ryan, Matthew S. Davids, Jennifer L. Crombie et al.|Blood|2022Cited by 8
Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 BlockadeReid W. Merryman, Ann S. LaCasce, Justin Kline et al.|Blood|2024Cited by 3